– Phase 3 Clinical Trials in both MDS and Beta-Thalassemia Planned for 2015 –
Cambridge, Mass. – January 12, 2015 – Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.
“Acceleron is pioneering the discovery and development of protein therapeutics that unlock the body’s ability to build and repair cells and tissues, and we look forward to advancing all four of our innovative protein therapeutics into mid- and late-stage clinical trials this year,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
The major research and development objectives are highlighted below:
Sotatercept and Luspatercept in Rare Blood Disorders
• Complete phase 2 clinical trials of luspatercept and sotatercept in MDS and beta-thalassemia
• Finalize phase 3 clinical development plans with health authorities for MDS and beta-thalassemia
• Initiate phase 3 clinical trials in MDS
• Initiate phase 3 clinical trials in beta-thalassemia
Sotatercept in End-stage Renal Disease
• Initiate randomized, controlled stage of phase 2b clinical trial of sotatercept in end-stage renal disease patients
Dalantercept in Advanced Cancers
• Announce top line data from phase 2 trial of dalantercept with axitinib in renal cell carcinoma
• Demonstrate safety of combination of dalantercept and sorafenib in hepatocellular carcinoma
ACE-083 in Muscle Disorders
• Initiate phase 2 trial with novel muscle agent ACE-083
Pipeline Expansion
• Conduct IND-enabling work to advance at least one new protein therapeutic to the clinic in 2016
A slide presentation describing these research and development goals and other information is available on the "Events and Presentations" page in the Investors & Media section on the Company's website (http://investor.acceleronpharma.com/events.cfm)
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-ß) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
Help employers find you! Check out all the jobs and post your resume.
Cambridge, Mass. – January 12, 2015 – Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.
“Acceleron is pioneering the discovery and development of protein therapeutics that unlock the body’s ability to build and repair cells and tissues, and we look forward to advancing all four of our innovative protein therapeutics into mid- and late-stage clinical trials this year,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
The major research and development objectives are highlighted below:
Sotatercept and Luspatercept in Rare Blood Disorders
• Complete phase 2 clinical trials of luspatercept and sotatercept in MDS and beta-thalassemia
• Finalize phase 3 clinical development plans with health authorities for MDS and beta-thalassemia
• Initiate phase 3 clinical trials in MDS
• Initiate phase 3 clinical trials in beta-thalassemia
Sotatercept in End-stage Renal Disease
• Initiate randomized, controlled stage of phase 2b clinical trial of sotatercept in end-stage renal disease patients
Dalantercept in Advanced Cancers
• Announce top line data from phase 2 trial of dalantercept with axitinib in renal cell carcinoma
• Demonstrate safety of combination of dalantercept and sorafenib in hepatocellular carcinoma
ACE-083 in Muscle Disorders
• Initiate phase 2 trial with novel muscle agent ACE-083
Pipeline Expansion
• Conduct IND-enabling work to advance at least one new protein therapeutic to the clinic in 2016
A slide presentation describing these research and development goals and other information is available on the "Events and Presentations" page in the Investors & Media section on the Company's website (http://investor.acceleronpharma.com/events.cfm)
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-ß) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
Help employers find you! Check out all the jobs and post your resume.
